Weber Christophe Pierre 4

What Happened

• Christophe Pierre Weber, President & CEO and Director of Takeda Pharmaceutical (TAK), was awarded a total of 323,248 share‑equivalent awards on April 27, 2026 (three entries: 78,900; 165,370; and 78,978 units). Each line was reported as an award/grant (code A) at $0.00 per unit. The awards consist of performance‑based restricted stock units (RSUs) and related derivative/tax‑equivalent awards that vest subject to achievement of specified performance metrics.

Key Details

• Transaction date: 2026-04-27; filing date: 2026-04-28 (timely filing).
• Reported consideration: $0.00 per unit; total units reported = 78,900 + 165,370 + 78,978 = 323,248.
• Transaction codes: A = Award/Grant; one line reported as a derivative award.
• Shares owned after the transaction: Not disclosed in the provided filing excerpt.
• Notable footnotes from the filing:
  • F1/F3: Awards granted under a July 1, 2023 grant that vest in ordinary shares and American Depositary Shares (ADS) based on performance metrics (core revenue, core operating profit, R&D milestones); the Compensation Committee determined award amounts on April 27, 2026.
  • F2: “Includes 174,900 RSUs” that vest June 1, 2026 (125,000), June 1, 2027 (32,700) and June 1, 2028 (17,200).
  • F4: “Includes 369,378 RSUs” that vest July 1, 2026 (261,114), July 1, 2027 (72,384) and July 1, 2028 (35,850).
  • F5: Tax Obligation Awards are the economic equivalent of one Ordinary Share and, upon vesting, convert to a cash payment primarily to cover tax obligations.
• Filing timeliness: Reported the day after the awards were determined; within typical Form 4 reporting windows.

Context

• These are awards/RSUs (not open‑market purchases or sales). RSUs are conditional — they only convert to tradable shares or cash if vesting conditions are met, so they do not represent an immediate share sale or cash outlay by the insider.
• One award type is a tax‑equivalent payment (F5) that will be settled in cash on vesting to cover taxes rather than delivering a share.
• For retail investors, awards can signal executive compensation tied to performance targets but are not the same as a purchase (which some investors view as a stronger bullish signal).